We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Topics » Pharmaceuticals » Research and Development

Research and Development
%{topic} RSS Feed RSS

FDA Stops Bluebird Bio’s Sickle Cell Study After Serious Side Effects

February 26, 2021
The company also temporarily stopped all sales of its approved gene therapy Zynteglo, a treatment for the blood disorder beta thalassemia that uses the same the same lentiviral vector. Read More

Parkinson’s UK Spins Off Biotech to Develop Possible Treatment

February 26, 2021
The initial trial didn’t meet its critical endpoint, but it did reveal some evidence that the treatment could possibly reverse Parkinson’s. Read More

Study Finds Statins Don’t Cause or Worsen Muscle Pain

February 26, 2021
A new UK study has found that statins did not have any overall effect on muscle symptoms in patients who had previously reported them when taking the medications, suggesting that statins may not responsible for the muscle pains associated with taking them. Read More

Israel Finds Pfizer/BioNTech Vaccine Effective Across All Age Groups

February 26, 2021
The Pfizer/BioNTech COVID-19 vaccine showed the same effectiveness for all age groups — including individuals over age 60 — confirmed a new study from Israel that included almost 1.2 million individuals. Read More

Pfizer and BioNTech Kick Off Study Evaluating Booster Shot Against South African Variant

February 26, 2021
Pfizer and BioNTech have begun assessing the safety and immunogenicity of a third dose of their COVID-19 vaccine against the coronavirus’ South African mutation and other potential viral variants. Read More

NIH to Begin Evaluating Moderna Vaccine Modified Against South African Strain

February 25, 2021
The NIH’s National Institute of Allergy and Infectious Diseases (NIAID) will soon begin a phase 1 clinical trial of Moderna’s variant-specific COVID-19 vaccine candidate, mRNA-1273.351, which has been tailored to better protect against the virus’ South African mutation. Moderna will also conduct trials of its own. Read More

Fujifilm Could Relaunch Avigan Study for COVID-19

February 24, 2021
Fujifilm is betting that Avigan, which inhibits the RNA polymerase enabling the flu virus to replicate, will work against the coronavirus, another RNA virus. Read More
Rocket Launches

GSK and Sanofi Launch Phase 2 Vaccine Study After Delay

February 24, 2021
In December, GSK and Sanofi suffered a setback during their phase 1/2 trial, when their vaccine was found to produce only a weak immune response in older patients. Read More
Process Success blocks

Relugolix Shows Benefit in Uterine Fibroid Late-Stage Study

February 23, 2021
Roughly three-quarters of women enrolled in the trial saw a 50 percent or greater reductions from baseline in menstrual blood loss volume during the last 35 days of treatment. Read More

GSK, Sanofi Kick Off Phase 2 Vaccine Trial Following December Delay

February 23, 2021
GlaxoSmithKline (GSK) and Sanofi have launched a phase 2 study evaluating their adjuvanted recombinant COVID-19 candidate, after delaying the trial by more than two months. Read More

Novavax Finishes Enrollment for U.S. Phase 3 COVID-19 Vaccine Trial

February 23, 2021
Novavax has announced that it has completed enrolling 30,000 participants in its late-stage U.S./Mexico pivotal trial of its COVID-19 vaccine, bringing its recombinant protein-based vaccine hopeful one step closer to potential FDA authorization. Read More
UKflag.jpg

UK to Launch First Human Challenge Study for COVID-19

February 22, 2021
The small-scale trial will include up to 90 healthy adult volunteers age 18 to 30 years who will be exposed to the virus in a controlled setting. Read More
Previous 1 2 3 4 5 6 7 8 9 … 197 198 Next

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Sanofi-Regeneron_Logos.png

    Sanofi’s and Regeneron’s Libtayo Wins FDA Approval for NSCLC

  • PerkinElmer logo

    PerkinElmer’s Rapid Point-of-Care COVID-19 Test Cleared in Europe

  • WhiteHouse.gif

    President Biden Issues Executive Order on U.S. Supply Chain

  • roche.gif

    Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing